| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| 00% | ₹1,013.5 0% | 4,600 | ₹9.8 0% | 5000% |
| 3750% | ₹795 0% | 4,800 | ₹3.25 75.67% | 1250% |
| - | - | 4,850 | ₹5 0% | 2,0000% |
| - | - | 4,900 | ₹10 0% | 2500% |
| - | - | 4,950 | ₹11.15 0.45% | 3,6250% |
| - | - | 5,000 | ₹8.5 0% | 5,0000% |
| 00% | ₹511.4 0% | 5,100 | ₹12.95 0% | 1,3750% |
| - | - | 5,200 | ₹20 0% | 3,6250% |
| 00% | ₹477.05 0% | 5,250 | ₹21.15 0% | 5000% |
| 5,0000% | ₹281.6 1.53% | 5,300 | ₹30.8 -2.53% | 15,2500% |
| 2500% | ₹421.45 0% | 5,350 | ₹43.85 -4.36% | 2,7500% |
| 1,3750% | ₹403.2 0% | 5,400 | ₹48.45 -1.72% | 22,3750% |
| 3,1250% | ₹364.9 0% | 5,450 | ₹59.4 -2.94% | 5,2500% |
| 13,2500% | ₹270.8 0% | 5,500 | ₹74.95 2.6% | 22,8750% |
| 1,2500% | ₹268.7 0% | 5,550 | ₹90.55 -0.43% | 2,6250% |
| 8,2500% | ₹182.7 1.1% | 5,600 | ₹109.35 0.09% | 9,5000% |
| 2,1250% | ₹154.45 0.91% | 5,650 | ₹132.05 0.15% | 5,7500% |
| 10,5000% | ₹133.25 2.77% | 5,700 | ₹157.1 0.38% | 7,7500% |
| 14,0000% | ₹107.1 -0.23% | 5,750 | ₹183.65 -0.75% | 4,7500% |
| 22,3750% | ₹87.9 -0.56% | 5,800 | ₹212.4 -0.3% | 1,7500% |
| 1,1250% | ₹77.4 7.5% | 5,850 | - | - |
| 29,2500% | ₹61.5 3.97% | 5,900 | ₹264 0% | 3750% |
| 14,2500% | ₹39.5 1.67% | 6,000 | ₹544.9 2.85% | 3750% |
| 1,5000% | ₹33.95 0% | 6,050 | ₹477.75 0% | 00% |
| 4,1250% | ₹24 0.84% | 6,100 | - | - |
| 3,6250% | ₹19.5 -0.51% | 6,150 | ₹733.1 0% | 2500% |
| 5,3750% | ₹17 2.4% | 6,200 | - | - |
| 6250% | ₹13.15 0% | 6,250 | - | - |
| 5,2500% | ₹11.15 1.82% | 6,300 | - | - |
| 2,7500% | ₹8 0% | 6,400 | - | - |
| - | - | 6,450 | ₹1,060 0% | 1250% |
| 2,0000% | ₹8.9 0% | 6,500 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
